The downturn at Novo Nordisk A/S could deal a further blow to Danish consumer confidence, with the drugmaker’s slumping ...
Axios on MSN
How Eli Lilly became the new king of GLP-1s
Eli Lilly is poised to leapfrog Novo Nordisk and become the dominant player in an anti-obesity drug market that could reach ...
Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as ...
Jacksonville Journal-Courier on MSNOpinion
Commentary: Taking a market-based path to affordable medicines — Merrill Matthews
Commentary: Americans generally pay more for brand-name drugs, but also pay significantly less for most generics: over 90% of ...
In what some news reports dubbed " an awkward moment ," CMS Administrator Mehmet Oz, MD, stepped up to the podium in the Oval Office last week to correct President Donald Trump on the status of GLP-1 ...
In a significant stride for chronic disease management, FDA granted approvals for Roche’s lupus nephritis treatment and Novo Nordisk’s cardiovascular-risk-reducing oral semaglutide for adults with ...
WeightWatchers said on Monday it will partner with Amazon to deliver medications including injectable GLP-1 obesity ...
Pfizer ( PFE) is number one and the leader in my list of "top 3 Big Pharma stocks." Over the last three quarters I have seen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback